SkinHealth Systems Inc. Appoints Three New Independent Directors to Board

SkinHealth Systems (Nasdaq: SKIN) appointed three independent directors—Kenneth Tripp, Dr. Sachin Shridharani, and E. Scott Beattie—effective April 17, 2026.

Rhea-AI Summary

SkinHealth Systems (Nasdaq: SKIN) appointed three independent directors—Kenneth Tripp, Dr. Sachin Shridharani, and E. Scott Beattie—effective April 17, 2026.

Each appointee brings sector expertise: medtech operations (Tripp), clinical aesthetics and trial experience (Shridharani), and global consumer brand leadership (Beattie). The Board currently totals 11 members and is expected to be nine after the 2026 Annual Meeting.

Positive

• Added three independent directors with complementary expertise
• Dr. Shridharani brings clinical trial leadership as Principal Investigator on 60+ trials
• E. Scott Beattie adds two decades of global beauty and brand scaling experience

Negative

• Board will decrease from 11 to 9 directors following the 2026 Annual Meeting
• Two current directors (Desiree Gruber and Dr. Philippe Schaison) not nominated for reelection

Argus Apr 23 session

-8.22% close to close Open Argus

Details

News Market Reaction – SKIN

On Apr 23, the first trading day after this news, SKIN closed 8.22% below the previous close.

Data tracked by StockTitan Argus for the Apr 23 session.

Key Figures

New independent directors: 3 directors Director service start date: April 17, 2026 Clinical trial leadership: More than 60 clinical trials +5 more

New independent directors

3 directors

Appointments to SkinHealth Systems board effective April 17, 2026

Director service start date

April 17, 2026

Effective date for Tripp, Shridharani, and Beattie appointments

Clinical trial leadership

More than 60 clinical trials

Trials where Dr. Shridharani served as Principal Investigator

Publications

Over 200 peer-reviewed articles/chapters

Authored by Dr. Shridharani in major medical journals

Global markets expansion

Over 120 markets

Elizabeth Arden footprint overseen by E. Scott Beattie

Navy service

25 years

Mr. Tripp’s U.S. Navy and Navy Reserve service

Current board size

11 directors

Board composition after new appointments

Expected board size

9 directors

Post-2026 annual meeting when two directors rotate off

Historical Context

5 past events · Latest: Mar 12

5 events

1. Mar 12

   Full-year earnings

   24h Move

   +19.8%

   Improved 2025 profitability and margins with 2026 guidance update.

2. Mar 09

   Product ecosystem news

   24h Move

   +3.5%

   Growing adoption of Hydrafacial and SkinStylus combination protocol.

3. Feb 26

   Earnings date notice

   24h Move

   +9.4%

   Announcement of timing for Q4 and full-year 2025 results.

4. Dec 04

   Consumer insights report

   24h Move

   -0.6%

   Release of third Skintuition Report on skin regeneration trends.

5. Nov 06

   Quarterly earnings

   24h Move

   +8.5%

   Q3 2025 results with better margins and adjusted EBITDA despite sales decline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

independent director, nasdaq, audit committee, nominating and corporate governance committee, +4 more

8 terms

independent director regulatory

"announced the appointment of three new independent directors to its Board"

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

nasdaq regulatory

"SkinHealth Systems Inc. (formerly The Beauty Health Company; Nasdaq: SKIN)"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

View in glossary

audit committee financial

"Mr. Tripp will serve on the Audit Committee."

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

nominating and corporate governance committee regulatory

"will serve on the Nominating and Corporate Governance Committee."

A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.

compensation committee financial

"Mr. Beattie will serve on the Compensation Committee."

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

board-certified medical

"Dr. Sachin Shridharani is a board-certified plastic surgeon"

Board-certified describes a professional—most often a physician or other clinical specialist—who has completed required specialty training and passed standardized exams administered by a recognized certifying board. For investors, board certification is a quick signal of verified expertise and credibility in critical roles such as clinical development, regulatory strategy, or medical advisory positions, and can reduce perceived execution and regulatory risk much like a credentialed mechanic reassures a buyer about a car’s condition.

clinical trials medical

"has served as Principal Investigator on more than 60 clinical trials."

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

sec regulations regulatory

"independent director under Nasdaq listing rules and applicable SEC regulations."

SEC regulations are the rules and requirements set by the U.S. Securities and Exchange Commission that govern how companies report financial information, disclose material events, register securities, and prevent fraud in the markets. They matter to investors because these rules create a predictable, transparent playing field—like traffic laws for the marketplace—helping investors assess risks, compare companies reliably, and reduce the chance of being misled or surprised by hidden problems.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Kenneth Tripp, Dr. Sachin Shridharani, and E. Scott Beattie bring deep expertise in medical devices, aesthetic medicine, and global consumer brands

LONG BEACH, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (formerly The Beauty Health Company; Nasdaq: SKIN), a global medical aesthetics company, today announced the appointment of three new independent directors to its Board of Directors (the “Board”): Mr. Kenneth Tripp, Dr. Sachin Shridharani, and Mr. E. Scott Beattie, each effective as of April 17, 2026.

“These three appointments reflect exactly the kind of Board we are building at SkinHealth Systems – one that brings extensive operational expertise in medtech, deep clinical authority in aesthetics, and proven leadership in scaling iconic global consumer brands," said Brent Saunders, Chairman of SkinHealth Systems. "Ken, Sachin, and Scott each bring perspectives that are directly aligned with where we are headed, and I look forward to the contributions they will make as we execute on our strategy.”

Kenneth Tripp joins the Board following a distinguished career in medical device manufacturing and supply chain leadership. He currently serves as Senior Vice President of Global Operations and Logistics at Zimmer Biomet Holdings, Inc., where, since 2018, he has led manufacturing, supply chain, engineering, and commercial operations across the company's global network. Previously, Mr. Tripp held senior operations roles at Cardinal Health Technologies, LLC and Covidien plc (now Medtronic plc). He also retired from the U.S. Navy and Navy Reserve after 25 years of service and holds an MBA with a focus on organizational leadership from Ashford University. Mr. Tripp will serve on the Audit Committee.

Dr. Sachin Shridharani is a board-certified plastic surgeon, founder of LUXURGERY^©, and Chief Medical Officer of SkinSpirit Essential. A nationally recognized innovator in aesthetic medicine, Dr. Shridharani developed the body and facial contouring technique Surgery in a Syringe℠ and has served as Principal Investigator on more than 60 clinical trials. He has co-authored over 200 peer-reviewed articles and textbook chapters in journals including Journal of the American Medical Association, Plastic and Reconstructive Surgery, and Aesthetic Surgery Journal, where he serves as section editor for cosmetic medicine. Dr. Shridharani also serves on the Board of Directors of The Aesthetic Society, a private organization dedicated to the safe practice of plastic surgery and cosmetic medicine. He earned his M.D. from the University of Missouri and completed his plastic surgery training at Johns Hopkins Hospital and an aesthetic fellowship at Manhattan Eye, Ear and Throat Hospital. Dr. Shridharani also obtained a Certificate Program in Surgical Leadership at Harvard Medical School and currently serves as an Associate Clinical Professor of Plastic Surgery at Washington University – St. Louis School of Medicine. Dr. Shridharani will serve on the Nominating and Corporate Governance Committee.

E. Scott Beattie brings more than two decades of senior leadership and board experience across the beauty and consumer products industry. Most notably, he served as Chairman and Chief Executive Officer of Elizabeth Arden, Inc., a U.S. based public company listed on Nasdaq, from 1998 to 2016, overseeing the company’s expansion into over 120 markets worldwide. Mr. Beattie currently serves as a director for Rexair, LLC, SENISCA Ltd, Crisp Inc., and Boosted AI. Mr. Beattie is also a founding investor in Newsela, Inc. and Grouper Education Inc. Mr. Beattie has previously served as a director for MAV Beauty Brands Inc., as Chairman of the Board for NexJ Systems Inc., and as a director and non-executive Vice Chairman of Revlon, Inc. He holds a bachelor’s degree in business administration and an MBA from the Ivey Business School at Western University, where he continues to serve on the advisory board. Mr. Beattie will serve on the Compensation Committee.

The Board, at the recommendation of the Board’s Nominating and Corporate Governance Committee, has determined that each of Mr. Tripp, Dr. Shridharani, and Mr. Beattie qualifies as an independent director under Nasdaq listing rules and applicable SEC regulations.

There are currently 11 directors comprising the Board after the appointments of Mr. Tripp, Mr. Beattie, and Dr. Shridharani to the Board. However, after consultation with each of Ms. Desiree Gruber and Dr. Philippe Schaison, two directors who are currently on the Board, the Board decided not to nominate Ms. Gruber or Dr. Schaison for reelection at the Company's 2026 annual meeting of stockholders (the “2026 Annual Meeting”). Ms. Gruber and Dr. Schaison will each serve out the remainder of their respective terms until it expires effective immediately following the adjournment of the 2026 Annual Meeting. Upon adjournment of the 2026 Annual Meeting, the Company expects that the Board will have 9 directors.

About SkinHealth Systems
SkinHealth Systems (NASDAQ: SKIN) is a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions designed to help consumers achieve superior skin health and support the success of providers. Anchored by Hydrafacial™, a leading and widely requested professional skincare treatment, and supported by complementary offerings including SkinStylus™ microneedling and HydraScalp™ with Keravive™, SkinHealth Systems combines advanced device technology, proprietary consumables, and clinical validation to deliver trusted treatment experiences through an omnichannel network of providers worldwide. Learn more at skinhealthsystems.com or follow us on LinkedIn. Local providers can be found at hydrafacial.com/find-a-hydrafacialist.

Forward-Looking Statements
Certain statements made in this release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding SkinHealth Systems Inc.’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside SkinHealth Systems Inc.’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Important factors that may affect actual results or outcomes include, among others: SkinHealth Systems Inc.’s ability to manage growth; SkinHealth Systems Inc.’s ability to execute its business plan; potential litigation involving SkinHealth Systems Inc.; changes in applicable laws or regulations; the possibility that SkinHealth Systems Inc. may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the “SEC”) and in the Company’s subsequent filings with the SEC such as on a Quarterly Report on Form 10-Q. There may be additional risks that the Company does not presently know of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. SkinHealth Systems Inc. does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contacts:
Press: press@skinhealthsystems.com
Investors: IR@skinhealthsystems.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who were appointed to the SkinHealth Systems (SKIN) board on April 17, 2026?

The company appointed Kenneth Tripp, Dr. Sachin Shridharani, and E. Scott Beattie as independent directors. According to the company, all three appointments were effective April 17, 2026 and add operations, clinical, and consumer-brand experience to the board.

What roles will the new SkinHealth Systems (SKIN) directors hold on board committees?

Mr. Tripp will join the Audit Committee, Dr. Shridharani will join Nominating and Corporate Governance, and Mr. Beattie will join Compensation. According to the company, each assignment aligns with their professional backgrounds and committee needs.

How will the SkinHealth Systems (SKIN) board size change after the 2026 Annual Meeting?

The board currently has 11 directors and is expected to have nine after the 2026 Annual Meeting. According to the company, two current directors will not be nominated for reelection and will serve until their terms expire at adjournment.

What experience does Dr. Sachin Shridharani bring to SkinHealth Systems (SKIN)?

Dr. Shridharani is a board-certified plastic surgeon, innovator in aesthetic medicine, and principal investigator on 60+ clinical trials. According to the company, he has authored 200+ peer-reviewed works and serves as an associate clinical professor of plastic surgery.

Why is E. Scott Beattie’s appointment significant for SkinHealth Systems (SKIN)?

Beattie brings over two decades leading beauty and consumer brands, including CEO of Elizabeth Arden and expansion into 120+ markets. According to the company, his experience supports scaling global brand and commercial strategies.